IGSF22: A Potential Drug Target for Cancer (G283284)

Target Name: IGSF22

NCBI ID: G283284

IGSF22

IGSF22: A Potential Drug Target for Cancer

IGSF22, also known as IGF21, is a protein that is expressed in the human placenta and has been identified as a potential drug target for the treatment of various diseases, including cancer. The IGF21 gene has been shown to play a role in the development and progression of cancer, and scientists are currently working to develop drugs that can target IGF21 to treat cancer cells.

One of the main reasons for the potential of IGF21 as a drug target is its role in the regulation of cell growth and division. IGF21 is a key regulator of the growth hormone pathway, which is responsible for the development and maintenance of tissues in the body. In cancer cells, the growth and division of cells are often uncontrolled, leading to the formation of tumors. By targeting IGF21, scientists hope to disrupt the growth and division of cancer cells and inhibit their growth.

Another potential mechanism by which IGF21 may be used to treat cancer is its role in the development of stem cells. IGF21 has been shown to play a key role in the development of stem cells, and researchers are investigating its potential as a drug target to treat cancer by inhibiting the production of stem cells. This could potentially lead to the loss of cancer cells, which could be an effective way to treat the disease.

IGF21 has also been shown to be involved in the regulation of cell adhesion. Cell adhesion is the process by which cells stick together to form tissues and organs, and is a critical part of the development and maintenance of these tissues. In cancer, the loss of cell adhesion can lead to the formation of tumors, and IGF21 may be used as a drug target to treat this by regaining cell adhesion.

In addition to its potential role in the regulation of cell growth and division, IGF21 has also been shown to play a key role in the development of cancer. Studies have shown that IGF21 is often overexpressed in cancer cells, and that inhibiting its activity may be an effective way to treat the disease. Additionally, IGF21 has been shown to promote the growth of cancer cells, which may also make it an attractive target for drug development.

While the potential uses of IGF21 as a drug target are still being explored, it is clear that IGF21 is an important protein that plays a critical role in the development and progression of cancer. Further research is needed to fully understand its role and to develop effective treatments for cancer.

Protein Name: Immunoglobulin Superfamily Member 22

The "IGSF22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGSF22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets